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Crossover studies can help the individualisation of care in Type 2 diabetes by matching 
patients to their most effect treatment. The MASTERMIND approach.  
 
Individualising or stratifying treatment  
Individualising care for patients with Type 2 diabetes is a central theme in both the 
American Diabetes Association (ADA) /European Association for the Study of Diabetes 
(EASD) 1 and National Institute for Health and Care Excellence (NICE)2 treatment guidelines. 
This individualisation involves setting an appropriate target HbA1c for an individual patient 
and determining choice of treatment primarily by risk of specific side effects and cost. 
Treatment could also be individualised by identifying subgroups of patients who respond 
particularly well to one type of glucose lowering therapy and/or have altered risk of 
treatment specific side effects.  As this applies to groups or strata of patients rather than an 
individual it has been termed “stratification”. A clear example of stratification in diabetes is 
that patients with HNF1A MODY have a 4-fold better response to sulphonylureas than 
matched subjects with type 2 diabetes3. This means excellent glycaemic control can be 
achieved in these patients using very low sulphonylurea doses.   
 
Type 2 diabetes lacks the homogeneity of a single gene disease; can we therefore identify 
subgroups of patients within this group who will respond better to one type of glucose 
lowering therapy?  On the face of it this should be possible; glucose lowering therapies act 
at different sites and have different mechanisms of action, and patients have differing 
pathophysiology even when they have a similar degree of hyperglycaemia.  Although 
theoretically attractive, to date the evidence for specific subgroups having a differential 
response has been limited.  This mainly reflects very little work being done to identify 
subgroups who respond well or badly to a medication and even less trying to identify 
subgroups where a specific treatment is favoured over another.  
 
Guidelines for treatment in the absence of data on stratification of glycose lowering 
In the absence of information about which patients will have the best glycaemic response to 
a therapy and limited data on comparative effects on long term outcomes it is hard to give 
guidance.  This results in the present algorithm for second and third line therapy seen in the 
recent NICE guidance where the drugs are listed in alphabetical order with limited guidance 
given on how to choose the optimum therapy.  Data on prescribing in the UK shows primary 
care doctors usually favours metformin and sulphonylurea as first and second line therapy.  
Third line treatment used to be insulin but now there is a wide choice of 3 oral therapies – 
thiazolidinediones, DPP-4 inhibitors (gliptins) and SGLT-2 inhibitors as well as injectable GLP-
1 receptor agonists and insulin.  Guidance on which therapies are likely to be most effective 
for an individual would be helpful to ensure patients receive a treatment most likely to be 
effective for them, and minimise cost, side effects and hyperglycaemia associated with 
initiation of an ineffective treatment. 
 
Current third line treatment  
 
 
 
Fig. 1 Abbreviated NICE guidelines for third line therapy4   
 
Preliminary data proposing possible stratification of glycaemic response in T2D 
MASTERMIND is an MRC funded collaboration examining stratification in Type 2 diabetes 
involving academic centres (Exeter, Dundee, Oxford, Glasgow, Bath, Newcastle, and KCL) 
and the pharmaceutical industry.  It aims to confirm variation in subgroup response to 
therapy and assess how this response is related to clinical features. Identification of these 
subgroups and evidence of improved or reduced response to a range of drug mechanisms 
will provide guidance in choice of glucose lowering therapy.  
 
Early work of this consortium and others has shown that such stratification is possible and 
that response to a therapy may be based on clinical characteristics and biological 
mechanisms. The PRIBA study of patients starting GLP-1RA therapy showed patients with 
low beta cell function, characterised by low C-peptide and positive GAD or IA2 islet 
antibodies had a markedly reduced response5.  
 
The group have also used routine GP data from over 110,000 patients with Type 2 diabetes 
together with data from clinical trials to identify potential stratification.  These include 
obese patients who experience a better glycaemic response when compared to non-obese 
patients when taking thiazolidinediones, but do worse when taking gliptins.  Also, within the 
normal range a higher GFR is associated with a better response to SGLT2 inhibitors, which 
inhibit the active reabsorption of glucose in the proximal tubule, whilst patients with a 
reduced but still normal GFR may see better glycaemic response when taking a renally-
excreted gliptin.   
 
These are simple, mechanistically intuitive observations which would easily transfer to 
clinical practice; BMI and GFR do not require expensive diagnostic tests. Having established 
differential response and identified associations between this response and drug 
mechanism, this potential stratification now needs to be tested in a trial.  
 
New approaches to test potential stratification 
The lack of previous work on differential response between subgroups leaves little 
methodological groundwork on which to build. The pilot work by the academic investigators 
and discussions with industrial colleagues quickly identified the need for new approaches to 
trials if new stratified approaches to therapy were to be found.  The challenge has been to 
identify an approach which combines the identification of subgroups that will respond well 
to one therapy and less well to another therapy. Randomised control trials with parallel-arm 
comparison do not try more than one therapy in the same patient.  
 
In analgesia therapy, n-of-1 trials have been used successfully to find the best drug for an 
individual patient by allowing them to trying multiple therapies and choosing the best 
option for them6. They are clearly superior in choosing the best treatment for an individual 
but lack the generalisability and robust evidence of an RCT.  
 
Crossover trials have the clear advantage of patients acting as their own control which 
reduces between-patient variability; the comparison of treatments is made on the same 
patient. This reduces the sample size needed compared to a parallel group trial design as 
well as cost. Randomised crossover trials can also be used to test specific subgroup 
hypotheses.  Type 2 diabetes lends itself to crossover trials as a stable chronic condition 
with an easily measurable outcome in glycated haemoglobin (HbA1c). The existence of 
multiple third line therapies with little guidance makes a crossover trial an ideal approach to 
stratification in this group of patients.  
 
TriMaster trial – a new study to test stratification 
TriMaster is the first three-way crossover study of third line glucose-lowering oral therapies, 
using an on-treatment HbA1c result as a primary outcome. It will test whether an informed 
evidence-based decision could be made on an individual’s likely response to therapy. 600 
patients on metformin and a sulphonylurea with an HbA1c greater than 58mmol/mol, will 
be recruited at 20 centres nationwide from the summer of 2016 for three years. These 
patients, who meet NICE guidelines for a third line treatment, will have underlying 
pathophysiology assessed in a mixed-meal tolerance test (MMTT) and baseline samples 
collected for analysis and storage for future biomarker discovery. They will receive 16 weeks 
of the three available oral therapies blinded, and in random order. At the end of each 16 
week treatment arm an on-treatment HbA1c will be taken and the three values compared at 
the study conclusion. Crucially, the measure analysed will be the achieved value after 16 
weeks rather than percentage or absolute change between either study or therapy baseline 
and end of treatment arm.  
 
 
 
Fig 2. TriMaster study diagram  
 
TriMaster will test two specific hypotheses that are based on the preliminary trial and 
routine data. Firstly that obese patients with a raised BMI (>30kg/m2) compared to non-
obese patients, will respond well to pioglitazone and less well to sitagliptin. Secondly, that 
patients with modestly reduced estimated glomerular filtration rate (eGFR 60-
90mls/min/1.73m2) compared to those with eGFR >90 will respond well to sitagliptin and 
less well to canagliflozin.  Patients will be randomised to four strata based on BMI and eGFR 
to ensure evenly sized groups, and the inclusion criteria will include all those who would be 
eligible for the three drugs in clinical practice.  
 
The crossover design has been carefully considered to avoid any discontinuation of third-
line therapy as washouts in the much shorter pilot study saw steadily increasing HbA1c and 
withdrawal from the study. A carryover effect has been minimised by a 16-week treatment 
period, where the final HbA1c reflects glycaemia over the preceding 8-12 week period and 
all three drugs have no continuing glucose-lowering effect one-four weeks after 
discontinuation. Residual carryover and treatment period interaction or order effect will be 
assessed at analysis.  
 
Side effects and patient preference  
Prescription of additional treatment in Type 2 diabetes is already individualised by risk of 
side effects, whether evidence-based or anecdotal. These risks are supported by trial and 
clinical data, but they based upon an average risk only. A prescribing clinician cannot 
balance risk against potential benefit in an individual patient because they lack evidence of 
subgroup response and individual risk of side effects.  To improve individualised care they 
need to link a patient’s likely response to their risk of side effects.  
 
A further advantage of the crossover approach is that a secondary outcome of patient 
preference and side effects can be assessed. TriMaster will collect data on patient 
experience of side effects and overall preference. Differential subgroup response to the 
three therapies will then be compared to incidence of side effects. These data and 
continuing exploration of routine clinical and trial data will establish any association of side 
effects and response, and ask whether it is possible to assess within a given subgroup of 
response whether some patients are more likely to experience side effects.  
 
Side effect data will include not only incidence and severity, but acceptability; the patient’s 
tolerance and willingness to take the therapy drug long term. The benefit of allowing 
patient’s to compare therapies will provide an insight into their decision process in clinical 
practice. Would an obese patient be prepared to tolerate a small percentage weight 
increase if accompanied by a pronounced improvement in HbA1c, or would a patient 
already prone to thrush be unwilling to increase this risk and opt for a drug which may be 
less effective in lowering glucose?  In the end it is the patient who should make this choice 
and this type of study will let them compare their experiences on three different drugs.  
 
Stratification long term  
Robust evidence for stratification by subgroup response, favoured therapy or experience of 
side effects would be a leap forward in therapy choice in Type 2 diabetes. A long term 
objective is for international and national patient care pathways to include, for the first 
time, evidence on which therapy is the most appropriate for specifically defined subgroups 
of patients based on glycaemic response and side effect profile.  We hope the TriMaster 
study will be a first step in this direction.  
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